TNFR1

AI Proteins to Attend BIO 2024; Company Provides Update on Technology Platform and Programs

Retrieved on: 
星期四, 五月 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Diabetes, Patient, Hope, Bone marrow, Protein, Obesity, Molecular biology, De novo, IND, DSM-IV codes, Psoriasis, AI, Inflammation, Cancer, TNFR1, Systemic inflammation, BIO, Crohn's disease, Weight loss, Therapy, Antibody, Lead, Rheumatoid arthritis, Engagers, Fine chemical

Unlike antibodies, these proteins can be engineered to achieve higher specificity, valency, stability, and efficacy, opening new avenues for therapeutic interventions.

Key Points: 
  • Unlike antibodies, these proteins can be engineered to achieve higher specificity, valency, stability, and efficacy, opening new avenues for therapeutic interventions.
  • We have robust business development activities underway with pharmaceutical partners to further leverage our unique technology platform and programs.
  • Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins.
  • Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.

Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases

Retrieved on: 
星期四, 一月 18, 2024
Patient, TNF, Biotechnology, AI, Protein, Inflammation, TNFR1, FDA, Therapy, Pharmaceutical industry

Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.

Key Points: 
  • Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.
  • Under the agreement, the companies will jointly conduct and share the costs of the program and will co-own any resulting data.
  • With current TNF-alpha pathway inhibitors being injectables, there is a major opportunity to develop oral anti-inflammatory medicines with differentiated best-in-class safety and efficacy.
  • This collaboration aims to combine promising features of our powerful miniprotein platform and Vivtex’s transformational oral biologics platform to develop anti-inflammatory therapeutics.”

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Retrieved on: 
星期一, 七月 10, 2023
Retina, Tissue, Smell, Neuron, TNFR1, TNF, GFAP, Ear, Axon, Pathology, Brain, Biomarker, Multiple sclerosis, Astrocyte, Remyelination, MS, Nose, Regeneration, Pharmacotherapy, Hearing, Drug development, Biology, Mouse, Microglia, Allograft inflammatory factor 1, Skin, Disease, Medical imaging

Boca Raton, Florida, July 10, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces important findings from data presented at The 16th European Meeting on Glial Cells in Health and Disease.  The conference runs July 8-12 in Berlin, Germany.

Key Points: 
  • Any damage to the myelin sheath compromises axon function preventing nerve cells from communicating and can result in nerve cell death.
  • Although the pathology of demyelination is easy to see, the biology of demyelination and remyelination is poorly understood.
  • The third surprise is that traditional biomarkers of astroglial and microglial activation, GFAP and Iba1 respectively, are increased in these myelin-promoting glial cells.
  • Therapeutic modulation of solTNF-TNFR1 signaling selectively in microglia promotes remyelination in the cortical grey matter.

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

Retrieved on: 
星期三, 十月 19, 2022
NASDAQ, TNF, Stada Arzneimittel, Respiratory disease, Mab, CEO, DKSH, Degenerative disease, Beauty, TNFR2, Communication, Cancer, Private Securities Litigation Reform Act, Health Canada, Marketing, Adalimumab, GLOBE, TNFR1, Growth, Review, Solution, Osteoporosis, Goal, Biosimilar, Terminology, Compliance, Immunoglobulin G, Caregiver, SEC, Patient, Partnership, Public, Group, Teva Pharmaceuticals, NOC, Forward-looking statement, COVID-19, Generic drug, Fine chemical, EU

Having already launched Simlandi, a biosimilar of Humira, we will continue to leverage our BIOJAMP and JAMP Care platforms for the benefit of patients and caregivers.

Key Points: 
  • Having already launched Simlandi, a biosimilar of Humira, we will continue to leverage our BIOJAMP and JAMP Care platforms for the benefit of patients and caregivers.
  • The partnership with JAMP Pharma will allow us to accelerate towards establishing a leadership position in the Canadian biosimilars market, said Robert Wessman, Founder and Executive Chairman of Alvotech.
  • In February 2022, JAMP Pharma announced the creation of BIOJAMP as part of its goal to establish itself as a leader in the Canadian biosimilars market.
  • BIOJAMP and the JAMP Care patient support program, are both designed to simplify the process for patients and caregivers of transitioning to lower-cost biosimilar medicines.

BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease

Retrieved on: 
星期三, 九月 7, 2022
Interferon gamma, Inflammation, Insulin resistance, AES, Treatment, Rheumatoid arthritis, Alzheimer's disease, Research, NASDAQ, Cognition, Glossary of biology, Dementia, Global, NF-κB, Psoriasis, IL23, Cytokine, JNK, Patent, TNF, Neurotoxicity, ADAS, GLOBE, MCI, Neuroinflammation, Mini–Mental State Examination, Use, Conference, TNFR1, Company, Placebo, Immune system, Phosphorylation, Annual conferences, Biomarker, Patrick Groc, AD, IKK, ERK, MMSE, Oxidative stress, Patient, Medicine, Pharmaceutical industry, Tumor necrosis factor

Reductions in TNFa (considered to be an initial factor driving inflammation) after NE3107 treatment are significantly correlated with improvement in cognition.

Key Points: 
  • Reductions in TNFa (considered to be an initial factor driving inflammation) after NE3107 treatment are significantly correlated with improvement in cognition.
  • NE3107 is the only molecule in this group that is pursuing a two-pronged approach targeting both neuroinflammation and insulin resistance.
  • Initial results showed that the measurements for most patients improved with NE3107 treatment, although MCI/mild AD patients showed greater change.
  • The Phase 2 trial (NCT05083260) is enrolling 40 patients to examine NE3107 in Parkinsons disease (PD) with two design objectives.

Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs

Retrieved on: 
星期二, 七月 5, 2022
Patient, Research, TNFR1, Delaware General Corporation Law, Cancer, Company, Lists of diseases, ROW, Degenerative disease, Partnership, Therapy, Private Securities Litigation Reform Act, Autoimmune disease, Rheumatoid arthritis, Pharmaceutical industry, Enosis (butterfly)

DOVER, Del., July 5, 2022 /PRNewswire/ -- Enosi Therapeutics, a Delaware Corporation, focused on providing industry-leading therapeutics for cancer and autoimmune diseases, has announced a partnership with Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi's pipeline for Greater China.

Key Points: 
  • Both programs have the potential to be used as cross-over drugs to treat cancer and autoimmune diseases.
  • With technical support from Enosi, Danuo will fund development in China and provide Enosi with data to use in its own filings in ROW.
  • Enosi Therapeutics is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer.
  • Enosi Therapeutics combines expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody's unique combination of medical, scientific and management expertise to expand therapeutic options.

Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine Research

Retrieved on: 
星期六, 十一月 27, 2021
World Health Organization, National academy, Emergency Use Authorization, Death, Juvenile idiopathic arthritis, Federation of European Pharmacological Societies, Cardiac myxoma, Signal transduction, Rheumatology, History, Risk, Nobel Prize, Castleman, World, Drug development, Lists of diseases, Food, IL-1, Interleukin-1 family, Degenerative disease, Lecture, Cancer, Mouth, Ventilation, Tocilizumab, Research, Castleman disease, TNF, News, National, Conference, Physiology, Medical school, TNFR1, Clinical trial, Human, COVID-19, Cytokine, Taipei Medical University, Interleukin 6, DRS, APFP, Tang Prize, Type 2 diabetes, Patient, Systemic, IL-1R, US Food Sovereignty Alliance, Inflammation, Translation, JIA, Novartis, Rheumatoid arthritis, IL-6, RNA, Canakinumab, Fibrosis, Pharmaceutical industry

Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.

Key Points: 
  • Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.
  • It was a journey that took them from basic research to drug development and clinical application.
  • These three lectures by the 2020 Tang Prize laureates in Biopharmaceutical Science will be premiered on the Tang Prize YouTube channel from 4 p.m. to 7 p.m. (GMT+8) on November 27.
  • To watch the complete version of the "2020 Tang Prize Laureate's Lectures for Biopharmaceutical Science," please consult the schedule below.

Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine Research

Retrieved on: 
星期六, 十一月 27, 2021
Lecture, Systemic, Taipei Medical University, National, Degenerative disease, National academy, Conference, Translation, Medical school, Federation of European Pharmacological Societies, Rheumatoid arthritis, TNFR1, IL-6, Inflammation, COVID-19, Cytokine, Research, Nobel Prize, Interleukin 6, Science, DRS, APFP, TNF, Interleukin-1 family, Pharmaceutical industry

Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.

Key Points: 
  • Charles Dinarello, Marc Feldmann, and Tadamitsu Kishimoto, providing valuable informaiton on the role cytokines play in inflammation and the COVID-19 disease as well as possible treatments.
  • In 1977, the research outcomes were published in the Proceedings of the National Academy of Sciences.
  • He also shed light on IL-6's effects on autoimmune diseases and how IL-6 can trigger cytokine storms.
  • To help the public gain a better understanding of the latest progress made in biomedical sciences, the Tang Prize Foundation will make these three lectures available on its official website ( https://www.tang-prize.org ) afterwards.